R
Raymond J. Andersen
Researcher at University of British Columbia
Publications - 540
Citations - 18331
Raymond J. Andersen is an academic researcher from University of British Columbia. The author has contributed to research in topics: Chemistry & Androgen receptor. The author has an hindex of 67, co-authored 521 publications receiving 16758 citations. Previous affiliations of Raymond J. Andersen include Scripps Institution of Oceanography & Kanazawa University.
Papers
More filters
Journal ArticleDOI
Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast.
Ainslie B. Parsons,Andres Lopez,Inmar E. Givoni,David E. Williams,Christopher A. Gray,Justin Porter,Gordon Chua,Richelle Sopko,Renee L. Brost,Cheuk-Hei Ho,Jiyi Wang,Troy Ketela,Charles Brenner,Julie A. Brill,G. Esteban Fernandez,Todd C. Lorenz,Gregory S. Payne,Satoru Ishihara,Yoshikazu Ohya,Brenda J. Andrews,Timothy P. Hughes,Brendan J. Frey,Todd R. Graham,Raymond J. Andersen,Charles Boone +24 more
TL;DR: A compendium of "chemical-genetic interaction" profiles by testing the collection of viable yeast haploid deletion mutants for hypersensitivity to 82 compounds and natural product extracts is generated, found to disrupt calcium homeostasis and phosphatidylserine was recognized as a target for papuamide B, a cytotoxic lipopeptide with anti-HIV activity.
Journal ArticleDOI
Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor
Raymond J. Andersen,Nasrin R. Mawji,Jun Wang,Gang Wang,Simon Haile,Jae-Kyung Myung,Kate Watt,Teresa Tam,Yu Chi Yang,Carmen Adriana Banuelos,David E. Williams,Iain J. McEwan,Yuzhou Wang,Marianne D. Sadar +13 more
TL;DR: This work identifies EPI-001, a small molecule that blocked transactivation of the NTD and was specific for inhibition of AR without attenuating transcriptional activities of related steroid receptors.
Journal ArticleDOI
A molecular barcoded yeast ORF library enables mode-of-action analysis of bioactive compounds.
Cheuk Hei Ho,Leslie Magtanong,Sarah L. Barker,David Gresham,Shinichi Nishimura,Paramasivam Natarajan,Judice L. Y. Koh,Justin Porter,Christopher A. Gray,Raymond J. Andersen,Guri Giaever,Corey Nislow,Brenda J. Andrews,David Botstein,Todd R. Graham,Minoru Yoshida,Charles Boone +16 more
TL;DR: A yeast chemical-genomics approach designed to identify genes that when mutated confer drug resistance, thereby providing insight about the modes of action of compounds is presented, and a new class of sterol-binding compounds is discovered.
Journal ArticleDOI
An androgen receptor N-terminal domain antagonist for treating prostate cancer
Jae-Kyung Myung,Carmen Adriana Banuelos,Javier Garcia Fernandez,Nasrin R. Mawji,Jun Wang,Amy H. Tien,Yu Chi Yang,Iran Tavakoli,Simon Haile,Kate Watt,Iain J. McEwan,Stephen R. Plymate,Raymond J. Andersen,Marianne D. Sadar +13 more
TL;DR: Investigation of EPI-001 finds that EPI analogs covalently bound the NTD to block transcriptional activity of AR and its splice variants and reduced the growth of CRPC xenografts, suggesting that the development of small-molecule inhibitors that bind covalent to intrinsically disordered proteins is a promising strategy for development of specific and effective anticancer agents.